Nuvalent NUVL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Nuvalent (NUVL) Core Market Data and Business Metrics
Latest Closing Price
$70.46Price-Earnings Ratio
-17.93Total Outstanding Shares
66.16 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
One Broadway, 14th Floor, Cambridge, MA, 02142
Historical Stock Splits
If you bought 1,200,000 shares of NUVL before March 10, 2017, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| March 10, 2017 | 1-for-1200000 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 677,942 Shares | 8.1 | 3/14/2025 | 5,490,328 Shares |
| 419,465 Shares | 13.23 | 2/28/2025 | 5,550,068 Shares |
| 402,633 Shares | 13.59 | 2/14/2025 | 5,472,017 Shares |
| 462,991 Shares | 12.37 | 1/31/2025 | 5,726,913 Shares |
| 564,069 Shares | 10.65 | 1/15/2025 | 6,007,176 Shares |
| 539,284 Shares | 10.55 | 12/31/2024 | 5,691,654 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $568.88 Million |
| Net Cash Flow From Financing Activities, Continuing | $568.88 Million |
| Net Cash Flow From Investing Activities | $-573.51 Million |
| Net Cash Flow From Operating Activities | $-185.06 Million |
| Net Cash Flow, Continuing | $-189.70 Million |
| Net Cash Flow From Investing Activities, Continuing | $-573.51 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Research and Development | $217.77 Million |
| Revenues | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Operating Expenses | $280.37 Million |
| Net Income/Loss | $-260.76 Million |
| Diluted Earnings Per Share | $-3.93 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-260.85 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-90,000 |
| Comprehensive Income/Loss Attributable To Parent | $-260.85 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $38.34 Million |
| Liabilities | $71.96 Million |
| Accounts Payable | $5.22 Million |
| Wages | $10.45 Million |
| Liabilities And Equity | $1.14 Billion |
| Current Assets | $1.13 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||